SCHEMBL2146338

SCHEMBL2146338

N#Cc1ccccc1-c1c(C=NO)c2ccccc2n1-c1ccc(O)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 4/20 0.42
ESR1 P03372 2/20 0.34
MAPT P10636 3/20 0.33
LMNA P02545 3/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
GAA P10253 1/20 0.32
TDP2 O95551 2/20 0.31
HPGD P15428 1/20 0.31
GFER P55789 1/20 0.31
RECQL P46063 1/20 0.31
POLB P06746 1/20 0.31
KLK7 P49862 1/20 0.31
IMPDH2 P12268 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2146457 0.84 ESR2 (0.34) ESR2ESR1MAPTLMNAMEN1
SCHEMBL2146622 0.83 LMNA (0.32) ESR2MAPTLMNAMEN1KMT2A
SCHEMBL2146484 0.82 MAPT (0.34) ESR2ESR1MAPTLMNASMN1; SMN2
SCHEMBL2146478 0.82 MAPT (0.34) ESR2ESR1MAPTLMNASMN1; SMN2
SCHEMBL2146611 0.80 MAPT (0.35) MAPTLMNAMEN1KMT2AKDM4E
SCHEMBL2146432 0.79 MAPT (0.46) ESR2ESR1MAPTLMNAMEN1
SCHEMBL2146435 0.79 MAPT (0.46) ESR2ESR1MAPTLMNAMEN1
SCHEMBL2147551 0.76 MAPT (0.34) ESR2ESR1MAPTLMNAMEN1
SCHEMBL2147547 0.76 MAPT (0.34) ESR2ESR1MAPTLMNAMEN1
SCHEMBL2146335 0.76 ESR2 (0.43) ESR2ESR1SMN1; SMN2KDM4ETDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US claimed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP claimed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO claimed
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US disclosed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP disclosed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, GPER1 ESR2 4/4885ESR1 1/4885MAPT 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.